ProCE Banner Activity

Treatment Considerations for Patients With Essential Thrombocythemia: A Conversation Between Experts

Clinical Thought

Two experts discuss their approach to managing patients with essential thrombocythemia, including the role of CALR mutations, cytoreductive therapy, and JAK inhibition.

Released: February 23, 2023

Expiration: February 22, 2024

No longer available for credit.

Share

Faculty

Prithviraj Bose

Prithviraj Bose, MD

Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Andrew Kuykendall

Andrew Kuykendall, MD

Assistant Member
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, Florida

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

GSK

Incyte Corporation

PharmaEssentia Corp

Disclosure

Prithviraj Bose, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol-Myers Squibb, Cogent, CTI BioPharma, Incyte, Karyopharm, MorphoSys, Novartis, Pharma Essentia, Sierra Oncology (GlaxoSmithKline); researcher: Blueprint, Bristol-Myers Squibb, Cogent, CTI BioPharma, Disc Medicine, Incyte, Ionis, Kartos, MorphoSys, Telios.

Andrew Kuykendall, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol-Myers Squibb, CTI BioPharma, Imago, Incyte, MorphoSys, SDP Oncology, Sierra/GlaxoSmithKline.